An inflammatory cytokine signature predicts COVID-19 severity and survivalDiane M. Del Valle, Sacha Gnjatic, Manishkumar Patel et al.|Nature Medicine|2020Cited by 2.7k
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myelomaOliver Van Oekelen, Samir Parekh, Charles Gleason et al.|Cancer Cell|2021Cited by 216
Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumorsGeorge Mellgard, Che‐Kai Tsao, Vaibhav G. Patel et al.|Journal of Cancer Research and Clinical Oncology|2022Cited by 23
Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors.Qian Qin, Che‐Kai Tsao, Vaibhav G. Patel et al.|Journal of Clinical Oncology|2020Cited by 16
Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysisQian Qin, Che‐Kai Tsao, Tomi Jun et al.|Discover Oncology|2022Cited by 12